8-K: Vaxart Receives Nasdaq Extension and $9.27 Million BARDA Award for COVID-19 Oral Vaccine

Vaxart secures a Nasdaq extension to regain compliance with minimum bid price and a $9.27 million BARDA award to advance its oral COVID-19 vaccine.

Summary

• Vaxart has been granted an extension by Nasdaq until July 15, 2024, to meet the minimum $1.00 bid price requirement for continued listing.
• The company received a $9.27 million award from BARDA to prepare for a Phase 2b clinical study of its oral pill XBB COVID-19 vaccine.
• The Phase 2b study will involve 10,000 subjects and compare Vaxart's oral vaccine against an approved mRNA vaccine.
• Vaxart's oral vaccine is designed to be thermostable, potentially overcoming needle-phobia and offering broader, longer protection due to both systemic and mucosal immune responses.
• The BARDA award is part of the Project NextGen initiative, a $5 billion program by the U.S. Department of Health and Human Services to develop innovative COVID-19 vaccines and therapeutics.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. The BARDA award is a significant positive, but the ongoing Nasdaq compliance issue and the risks associated with clinical development temper the overall sentiment.

Positives

• The Nasdaq extension provides Vaxart with additional time to regain compliance with listing requirements.
• The BARDA award validates Vaxart's oral vaccine platform and provides significant funding for clinical development.
• The Phase 2b study has the potential to demonstrate the efficacy and advantages of Vaxart's oral vaccine.
• The oral vaccine's thermostability and potential for mucosal immunity are significant advantages over traditional vaccines.
• The BARDA award is part of a larger $5 billion initiative, indicating strong government support for innovative vaccine technologies.

Negatives

• Vaxart is still not in compliance with Nasdaq's minimum bid price requirement, which could lead to delisting if not resolved by July 15, 2024.
• The company is dependent on the success of its clinical trials and regulatory approvals.
• There is no guarantee that the oral vaccine will be successful or achieve broad market acceptance.
• The company faces competition from other vaccine developers.

Risks

• Vaxart may not be able to regain compliance with the Nasdaq minimum bid price requirement by the July 15, 2024 deadline.
• Clinical trial results may not be favorable, and regulatory approvals may not be granted.
• The company may face challenges in scaling up production and commercializing its oral vaccine.
• Vaxart may not be able to obtain sufficient capital to fund its operations.
• The company faces risks related to intellectual property protection and competition.

Future Outlook

Vaxart intends to actively monitor its stock price and explore options to regain compliance with Nasdaq listing requirements. The company plans to move forward with its oral COVID vaccine program, supported by the BARDA award, and believes its platform has the potential to revolutionize vaccination against infectious diseases.

Management Comments

• Dr. Michael Finney, Vaxart's Interim CEO, stated that they are honored to receive the BARDA award, which will support the innovative approach of their oral pill vaccine platform.
• Dr. James F. Cummings, Vaxart's Chief Medical Officer, believes their oral pill vaccine offers the chance to overcome needle-phobia and provide broader, longer protection than current vaccines.

Industry Context

This announcement highlights the ongoing efforts to develop more effective and accessible COVID-19 vaccines. Vaxart's oral pill vaccine platform aligns with the industry's focus on innovative delivery methods and broader protection against variants. The BARDA award reflects the government's commitment to supporting these advancements.

Comparison to Industry Standards

• Vaxart's oral vaccine approach is a departure from the mRNA vaccines that dominate the current market, such as those from Pfizer/BioNTech and Moderna.
• The focus on mucosal immunity is a key differentiator, as most current vaccines primarily induce systemic immunity.
• The thermostability of Vaxart's vaccine is a significant advantage over mRNA vaccines, which require cold storage.
• The 10,000-subject Phase 2b study is a substantial undertaking, comparable to large-scale trials conducted by major pharmaceutical companies.
• Companies like Novavax are also exploring protein-based vaccines, but Vaxart's oral delivery method is unique.

Stakeholder Impact

• Shareholders face the risk of delisting if Vaxart does not regain compliance with Nasdaq requirements.
• The BARDA award and potential success of the oral vaccine could positively impact shareholder value.
• Employees may benefit from the company's growth and development.
• Customers and the public could benefit from a more accessible and effective COVID-19 vaccine.
• Suppliers and partners may see increased business opportunities.

Next Steps

• Vaxart will actively monitor its stock price to regain compliance with Nasdaq listing requirements.
• The company will prepare for and conduct the Phase 2b clinical study of its oral COVID-19 vaccine.
• Vaxart will continue to develop its oral vaccine platform for other infectious diseases.

Key Dates

Keywords

Vaxart, oral vaccine, COVID-19, BARDA, Nasdaq, clinical trial, Project NextGen, minimum bid price, thermostable, mucosal immunity